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In figure 1 the difference in image quality can be seen going 
from 133 mAs (optimized protocol) to 1064 mAs (standard 
pelvic protocol).  
 
 
 
Results: For a scan in the head region going from Head1 to 
Head2 protocol reduced the mean dose to lens. For the 1 
year old child the dose is reduced from 6,6mGy to 1,7mGy. 
For the 5 years old child from 6,6mGy to 1,4mGy.  
For the 10 years old child form 6,6mGy to 1,4mGy. For a scan 
in the Pelvis region changing the protocol from Thorax to 
Pelvis increased the dose to the Breast from 0,2 to 0,7mGy 
and Gonads from 13,6 to 57,8mGy for a 5 years old child. For 
a 10 years old child the breast dose is increased from 0,1 to 
0,4 mGy and gonads from 11,8 to 46,0 mGy.  
With daily image guidance kVCBCT is performed up to 30 
times. For the five year old child it is an extra dose to the 
gonads of 30 x 44,2 mGy = 1,3Gy changing the protocol from 
thorax to pelvis.  
As seen on figure 1 the image quality drops going from pelvis 
to thorax protocol in the pelvic areas, but the opportunity for 
bone match is just as good with the thorax protocol. 
 
Conclusion: It matters what protocol is used for the kVCBCT 
uptake. It is possible to reduce the dose remarkably when 
choosing the most optimized protocol.  
Changing the scan range for head to avoid the lens reduce 
the lens dose with 471%. Another area where the scan range 
could be of great interest is the thorax region for girls. The 
radiation sensitive breast tissue can be spared if an 
appropriate scan range is chosen. 
The image quality drops when mAs is reduced. But be aware 
of the purpose of the image. Often it is not necessary to see 
the soft tissue, since a bone match is performed. Being able 
to evaluate on bones does not require a high image quality. 
The next step is to define new dose reduced protocols for 
kVCBCT for each age group 1, 5 and 10 years, and the work 
will be finished before ESTRO 2016. 
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Purpose or Objective: To investigate if VMAT shows any 
disadvantage in terms of reduction of second cancer risk 
(SCR) compared to 3DCRT using different high dose 
fractionation schemes in patients treated with RT for rectal 
cancer (RC) 
 
Material and Methods: 25 patients with stage I-III RC and 
pre- or postoperative RT were included in this ethics-
approved retrospective study. Planning CT data prior to RT 
were used. CTV for rectal cancer was delineated using RTOG 
contouring atlas. Organs at risk (OAR) (ICRP 2007) contoured 
on each CT data set were bladder, colon, sigmoid, bone, 
gonads, uterus, skin, small intestine, muscle, anus. 
PTV=CTV+5 mm. 3-field technique 6/15 MV 3DCRT and 6 MV 
VMAT plans were created (Eclipse, v.10, AAA-algorithm). 
Doses prescribed were 25x1.8 Gy and 5x5 Gy, respectively. 
Carcinogenesis model to estimate SCR emphasizes cell 
kinetics of radiation-induced cancer by mutational processes 
was used, integrating cell sterilization processes described by 
the LC model and repopulation effects. Model parameters 
were obtained by fits to epidemiological, cancer specific 
carcinogenesis data for carcinoma and sarcoma induction. 
From DVHs of structures of interest SCR in relation to organ 
equivalent dose (OED) was calculated. OED was converted to 
excess absolute risk for a western population for each organ 
as well as for all organs together. Resulting lifetime SCR from 
specific radiotherapy treatment was determined by lifetime 
attributable risk (LAR) by an integration of excess absolute 
risk from age at RT to lifetime expectancy (90 years) 
 
Results: Mean LAR was highest for organs adjacent or close 
to PTV. Total LAR for VMAT and 3DCRT was 2.4-3.0% and 2.0-
2.7%, respectively. For 5x5 Gy LAR was 1.4-1.9% for VMAT 
and 1.2-1.6% for 3DCRT and half as high as using 25x1.8 Gy. 
Median percentage LAR difference for OAR was significantly 
higher for VMAT irrespective of fractionation, and highest for 
bladder and colon. Individual differences in LAR ranged from 
0.2-15.9% for 25x1.8 Gy and 0.1-9.6% for 5x5 Gy. Size and 
shape of PTV influenced SCR, and was highest for age≤40 
years. For a patient with additional lifetime of 60 years, LAR 
was 10% for 25x1.8 Gy and 6% for 5x5Gy. No difference was 
detected using VMAT or 3DCRT 
 
Conclusion: For bladder and colon LAR is lower using 3DCRT, 
however difference is small. Compared to epidemiological 
data (Birgisson J Clin Oncol 2005) SCR is smaller when using a 
hypofractionated schedule treating RC. Total SCR is 2% at 
normal life expectancy. Risk is highest for young patients 
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Purpose or Objective: There is a growing awareness of dose 
delivered to parts the body outside the target volume during 
external beam radiotherapy. This concomitant dose could 
arise from external linac head leakage and scatter, scattered 
therapy dose outside the target volume, as well as non-
therapeutic doses from imaging for planning and delivery, 
such as CT planning scans. Total concomitant dose has 
increased steadily with the introduction of more imaging 
procedures to the treatment process and the drive for better 
images quality. Much of this exposure is only loosely 
monitored and it could be the case that the cumulative 
concomitant dose has a negative biological effect even within 
the context of radiotherapy [1]. To quantify the dose 
contributed by CT planning scans, a retrospective dose audit 
was carried out on a TOSHIBA AQUILION LB multislice CT 
scanner at Derby Teaching Hospitals in July 2015. 
 
Material and Methods: A cohort of 200 patients were 
identified, twenty each from ten of the most frequently used 
CT scanning protocols who were scanned in the 12 months 
immediately prior to the dose audit. Patients undergoing CT 
planning scans were initially identified in the Mosaiq 
Oncology Information System (Elekta, Crawley, UK) and 
subsequently interrogated via the PACSWeb system, 
(Centricity Enterprise Web V3.0, GE Healthcare, Barrington, 
IL). Data harvested from PACSWeb included: Number of 
slices, slice thickness, CTDIVOL, DLP, Patient sex, Patient 
Age, total scan time, transverse width and AP width. Mean 
Effective Dose (E) was derived from values of DLP for each 
examination using appropriately normalised coefficients. As 
yet, there are no published UK national guidelines for 
planning CT scans. However, to put the results of this audit 
into context we have compared local DLP and CTDIvol to 
similar values published for a previous UK national (diagnostic 
CT) dose audit [2]. The following relationships were 
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reported: CSA vs Age, CTDIvol vs CSA, DLP vs CSA, CTDIvol by 
Patient, DLP by Patient. 
 
Results: The mean scan length, DLP, CTDIvol and Effective 
Dose by Protocol were found for each protocol. The most 
significant result was that the DLP values from the Head & 
Neck protocol were tightly clustered but higher than one 
would normally expect. The mean DLP was a factor of 4 
greater than the head and neck reference level reported in 
the previous UK national (diagnostic CT) dose audit. 
 
 
 
Conclusion: The results from this CT dose audit can be used 
as local Radiotherapy Imaging Reference Levels (RIRL). They 
will be able to guide protocol optimisation, allow comparison 
with other similarly equipped radiotherapy departments and 
participation in regional and national audits. The higher than 
expected DLP values for the Head & Neck protocol 
highlighted here has prompted a reassessment of the 
scanning parameters and may lead to protocol optimisation. 
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Purpose or Objective: Radiation safety for softer flattening 
filter free (FFF) treatment beams when operating at their 
very high dose rates should be considered over that of their 
flattening filter (FF) counterparts. Existing shielding is usually 
adequate when replacing treatment units utilizing beams of 
FF only with FFF-beams of the same nominal energy(1). 
However, depending upon the existing shielding composition 
and thickness, workload, and occupancy factors, the 
instantaneous dose rate (IDR) may present a radiation safety 
concern. 
 
Material and Methods: A generalized analysis is presented 
with regards to replacing a unit which has only FF-beams to 
one with FFF-beams in a pre-existing bunker. Extra focus is 
placed on the situation that radiation levels around the 
treatment bunker are already at the radiation safety 
threshold for the unit being replaced. This threshold 
condition varies with the radiation safety regulations of the 
land. For example, the Canadian Nuclear Safety Commission 
(CNSC) imposes a condition that the IDR be less than 25 μSv/h 
to deem an area uncontrolled(3). The United States National 
Regulatory Council (US NRC) regulates the time averaged 
dose rate (TADR) to be less than 20μSv in any one hour(2).  
 
Results: It is demonstrated that in switching to FFF-beam 
treatment units that protection using existing shielding is 
maintained for annual and weekly equivalent dose protection 
levels. However, it is possible for the CNSC IDR condition to 
be exceeded at the highest dose rates for FFF-beams. Thus 
shielding modification should be considered along with the 
ALARA principle(4). An analysis of the latter point is 
presented in general and by example from such a treatment 
unit replacement at the London Regional Cancer Program. 
The US NRC regulation is not as stringent as the Canadian 
condition and is almost impossible to exceed if the conditions 
before replacement were met. The analysis of this result is 
presented in general. 
 
Conclusion: Care must be taken when considering 
thereplacement of radiation treatment units with FF-beams 
to those with FFF-beamswith respect to radiation protection. 
Radiation protection from the existingshielding is maintained 
for annual and weekly protection levels. However, IDR may 
present a radiation safety concern dependingupon radiation 
safety regulations in the country of its location. In 
Canada,the possibility exists that this threshold can be 
exceeded. The US NRCcondition is almost impossible to 
exceed. 
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Purpose or Objective: In image-guided radiotherapy, 
imaging dose varies greatly with the imaging technique. We 
here present imaging doses from planar and cone-beam CT 
(CBCT) imaging for three different on-board imaging 
techniques: the treatment beam line (TBL, 6 MV), a 
dedicated imaging beam line termed kView of nominally 1 MV 
(IBL), and a kilovoltage system (kVision) at 70-121 kV photon 
energy. We consider two collectives of patients with common 
IGRT indications: head-and-neck and prostate cancer. 
 
Material and Methods: In this study, we retrospectively 
analyzed imaging dose of 54 patients with head-and-neck 
cancer and 53 with prostate cancer treated in 2013. For all 
patients, the number of verification images (CBCT and axes) 
was determined, separately for the three systems (more than 
1000 images). The dose for each verification image was 
calculated in the Philips Pinnacle treatment planning system 
on a 2 mm grid using the collapsed cone algorithm. We 
evaluated the dose maximum and dose to the organs at risk, 
considering the total imaging dose, and for the techniques (6 
MV, IBL, kV, planar vs. CBCT) separately. 
 
Results: The calculated imaging doses are given in Table 1. 
Both the TBL and IBL modality entail considerable imaging 
dose, even for orthogonal axes. The maximum dose value for 
each image, averaged over all prostate patients, was 14.8 
cGy (6 MV CBCT)/ 2.8 cGy (19 %; 6 MV axes)/ 10.5 cGy (71 %; 
IBL CBCT)/ 2.1 cGy (14 %; IBL axes)/ 3.8 cGy (26 %; kV CBCT), 
where percentage values refer to the 6 MV CBCT dose. As can 
be seen, kV CBCT still amounts to 26 % the imaging dose from 
MV CBCT, and about twice the dose from IBL axes. Averaged 
over the collective of head-and-neck cancer patients, the 
maximum imaging dose was 8.4 cGy (6 MV CBCT)/ 2.6 cGy (31 
%; 6 MV axes)/ 6.2 cGy (74 %; IBL CBCT)/ 2.3 cGy (27 %; IBL 
axes)/ 0.9 cGy (11 %; kV CBCT). Here, the dose reduction 
from axial images was not as pronounced because less 
monitor units were used for MV CBCT. kV CBCT reduced the 
dose further because of low mAs values chosen by the auto-
exposure mechanism. 
 
